Navigation Links
Cleveland Clinic research: Most statin-intolerant patients can eventually tolerate statins
Date:9/9/2013

Monday, September 9, 2013, Cleveland: Most patients who report statin intolerance, including muscle aches and other side effects from the cholesterol-lowering drugs, can actually tolerate drugs from this class on subsequent trials, according to research from Cleveland Clinic recently released online and forthcoming in the September issue of the American Heart Journal. The study is the largest ever to examine the effects of re-challenging statin-intolerant patients.

Statins are among the most prescribed drugs in the world and are a first-line, highly effective therapy for patients with high cholesterol, which is a major risk factor in the development of cardiovascular disease. Statins have been shown to reduce cholesterol levels by as much as 20 to 40 percent at the lowest dose level. However, in clinical trials, about 5 to 10 percent of patients have been reported as suffering from statin-related side effects like muscle pain and liver enzyme abnormalities, making them statin intolerant. In observational studies which often incorporate patients not typically selected for clinical trials, including older patients, more women, and those with comorbidities the rate of statin intolerance is as high as 20 percent.

In these patients, physicians often try intermittent dosing of statins, instructing patients to take the medication every other day, for instance, instead of daily, to reduce side effects.

Researchers, led by Leslie Cho, M.D., Section Head of Preventative Cardiology and Rehabilitation in the Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic, analyzed the electronic medical records of 1,605 patients who were referred to Cleveland Clinic for statin intolerance between January 1995 and March 2010.

Dr. Cho and her colleagues found that 72.5 percent of patients who were previously reported to be intolerant to two or more statins were able to take drugs from the class on subsequent trials when they were overseen in Cleveland Clinic's preventative cardiology clinic and had their statin regimen carefully restarted. Further, 63.2 percent of previously statin-intolerant patients were able to tolerate a daily statin regimen, with only 9.3 percent going on intermittent statin therapy. While those patients who remained on a daily dose of statin saw their cholesterol lowered to a greater extent than those on intermittent statin dosing, Dr. Cho and her colleagues found that the intermittent group did benefit significantly from the statin therapy.

"Our study shows that patients who have experienced statin intolerance should, under the close care of their physician, continue to try other drugs in this class because there is a very good chance that they will eventually be able to tolerate long-term use of a statin and benefit from its cholesterol-lowering effects," said Dr, Cho. "Even if patients cannot tolerate a daily dose of a statin, it's possible to see a significant reduction in cholesterol levels from taking the drug less often, even as infrequently as once a week."

Still, Dr. Cho points out that, given how widely statins are prescribed, it's important to note that almost 30 percent of the patients in the study remained statin intolerant and required alternative therapies to treat their high cholesterol.


'/>"/>

Contact: Wyatt DuBois
duboisw@ccf.org
216-445-9946
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Cleveland Clinic research finds no benefit over placebo in ASSURE trial
2. Cleveland Clinic research finds blood pressure drug tends to slow coronary disease
3. Cleveland Clinic researcher finds genetic mutation in castration-resistant prostate cancer
4. CE Lectures on the Dental Treatment of Snoring and Sleep Apnea Include Rochester, Cleveland and Ft. Lauderdale, as Sleep Seminar Destinations
5. Cleveland Indians vs. Detroit Tigers Tickets: Cheap Concert Tickets Slashes Prices on All Indians vs. Tigers Tickets for August 5th - August 8th Series Progressive Field
6. National Transitions of Care Coalition to Host Regional Summit in Cleveland
7. Maroon 5 & Kelly Clarkson Ticket Prices Slashed for Concerts in Long Island, Holmdel, Cincinnati, Pittsburgh, Camden/Philly, Boston/Mansfield, Chicago, Cleveland & Detroi
8. Explorys Proud to Sponsor Cleveland GiveCamp
9. NEONI Participates in Healthcare Career Event at Cleveland Convention Center Grand Opening
10. Cleveland Clinic Laboratories to provide testing and diagnostic services to ACL Laboratories
11. Book of Mormon Tickets: Prices Slashed on Book of Mormon Tickets in New York, Chicago, Cleveland, Buffalo, Washington DC, Minneapolis, Houston and San Antonio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra ... care advancements to physician colleagues, skilled nursing facility medical directors and other clinicians ... Waters of Wound Care." , "At many of these conferences we get to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
Breaking Medicine Technology: